Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Script (including Q&A)

11/18/2021 | 12:02am EST

CHUGAI PHARMACEUTICAL CO., LTD.

ESG Meeting

November 16, 2021

Event Summary

[Company Name]

CHUGAI PHARMACEUTICAL CO., LTD.

[Company ID]

4519-QCODE

[Event Language]

JPN

[Event Type]

Analyst Meeting

[Event Name]

ESG Meeting

[Fiscal Period]

[Date]

November 16, 2021

[Number of Pages]

47

[Time]

10:00 - 11:32

(Total: 92 minutes, Presentation: 62 minutes, Q&A: 30 minutes)

[Venue]

Dial-in

[Venue Size]

[Participants]

[Number of Speakers]

5

Motoo Ueno

Representative Director, Deputy Chairman

Toshiaki Itagaki

Executive Vice President & CFO

Tsukasa Kusano

Vice President, Head of Clinical Development

Division

Shigehiro Yamada

Head of Sustainability Department

Seiji Saito

Digital Engineering Department

Toshiya Sasai

Head of Corporate Communications

Department

[Analyst Names]*

Hidemaru Yamaguchi

Citigroup Global Markets Japan Inc.

Kazuaki Hashiguchi

Daiwa Securities Co. Ltd.

Shinichiro Muraoka

Morgan Stanley MUFG Securities Co., Ltd.

*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

1

Presentation

Sasai: Let's get started. Ladies and gentlemen, thank you very much for taking time out of your busy schedules to participate in today's CHUGAI PHARMACEUTICAL ESG briefing. My name is Sasai from Corporate Communications, and I will be moderating today's session. Thank you.

In order to prevent the spread of the coronavirus infection, today's session will be conducted by both on-site presentation and conference call.

The agenda for today's briefing is shown on the screen in the hall, on the web screen, and on the second page of the presentation materials. Our presentation will be in line with the materials. Questions will be taken after all presentations have been completed. The Q&A is scheduled to take about 30 minutes.

Mr. Ueno, Chugai's Representative Director and Deputy Chairman, will now talk about sustainability and management. Thank you.

Ueno: Good morning, everyone. I'm Ueno. Thank you very much for attending the third Chugai ESG briefing.

The social and economic environment is changing rapidly. The coronavirus pandemic has contributed to this. We are facing a variety of societal issues, and we believe that dialogue with our stakeholders is essential in addressing these issues. Today's session will take just under an hour. Today, 110 people are joining us for this event. Of those, less than 10 people are in attendance at the venue. Last year, about 80 people attended the briefing, of whom 20 came to the venue. With the impact of COVID-19, I believe that this is part of the so- called New Normal, where digitalization creates new opportunities for meeting peoples' diverse needs.

Our contact with medical institutions continues to be strained by COVID-19. In this context, we have been holding webinars, which have been well received by doctors who are usually unable to participate due to long distances to travel. I think that hybrid events will continue to take hold in the future.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

2

First of all, I would like to talk about the subject of today's briefing. As I just mentioned, this is our third talk on this topic. In the first presentation, I gave an overview of Chugai's ESG initiatives. In the second presentation, last year, I gave an overview of our main themes.

According to the questionnaire we distributed, some investors said that they had a relatively good understanding of Chugai's individual ESG activities, but they wanted an explanation of how ESG relates to drug discovery and growth strategies. So this time, I'd like to go one step further and focus on how Chugai is promoting ESG as a management strategy, what we are doing, and what we want to do.

I would also like to mention that our management strategy and ESG activities are interdependent.

Going forward, we will continue to hold ESG briefings as well as review our ESG initiatives. We will do this through the PDCA cycle and through dialogue with stakeholders.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

3

Before I make a start on the main topic, I have a message from one of our outside directors.

This is Mr. Ichimaru. As you can see, at Board meetings and presentations, Mr. Ichimaru has given us his frank opinions and advice on ESG initiatives and dialogue with stakeholders.

With the support of outside directors, we would like to continue to make a commitment to ESG.

As mentioned in the second paragraph, in order to realize the " advanced and sustainable patient-centric healthcare " that Chugai advocates, it is necessary and important for each and every employee to consider business activities, including ESG, as a part of their own work, creating shared values in each workplace. It is necessary and important to have continuous dialogue on ESG to understand the expectations and requests from outside. These must be reflected in management, with this process running as a cycle.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 18 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2021 05:01:02 UTC.


ę Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD
01/21CHUGAI PHARMACEUTICAL : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia..
PU
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2021 975 B 8 565 M 8 565 M
Net income 2021 292 B 2 565 M 2 565 M
Net cash 2021 461 B 4 050 M 4 050 M
P/E ratio 2021 20,7x
Yield 2021 1,87%
Capitalization 6 051 B 53 179 M 53 139 M
EV / Sales 2021 5,73x
EV / Sales 2022 5,37x
Nbr of Employees 7 555
Free-Float -
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 680,00 JPY
Average target price 4 823,85 JPY
Spread / Average Target 31,1%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.47%53 179
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356